Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations

Catriona L Halliday, Sharon C.A. Chen, Sarah E. Kidd, Sebastian Van Hal, Belinda Chapman, Christopher H Heath, Andie Lee, Karina J Kennedy, Kathryn L. Daveson, Tania Christine Sorrell, C. Orla Morrissey, Deborah J E Marriott, Monica A Slavin

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)


Antifungal susceptibilities of non-Aspergillus filamentous fungal pathogens cannot always be inferred from their identification. Here we determined, using the Sensititre® YeastOne® YO10 panel, the in vitro activities of nine antifungal agents against 52 clinical isolates of emergent non-Aspergillus moulds representing 17 fungal groups in Australia. Isolates comprised Mucorales (n = 14), Scedosporium/Lomentospora spp. (n = 18) and a range of hyaline hyphomycetes (n = 9) and other dematiaceous fungi (n = 11). Excluding Verruconis gallopava, echinocandins demonstrated poor activity (MICs generally >8 mg/L) against these moulds. Lomentospora prolificans (n = 4) and Fusarium spp. (n = 6) demonstrated raised MICs to all antifungal drugs tested, with the lowest being to voriconazole and amphotericin B (AmB), respectively (geometric mean MICs of 3.4 mg/L and 2.2 mg/L, respectively). All Scedosporium apiospermum complex isolates (n = 14) were inhibited by voriconazole concentrations of ≤0.25 mg/L, followed by posaconazole and itraconazole at ≤1 mg/L. Posaconazole and AmB were the most active agents against the Mucorales, with MIC90 values of 1 mg/L and 2 mg/L, respectively, for Rhizopus spp. For dematiaceous fungi, all isolates were inhibited by itraconazole and posaconazole concentrations of ≤0.5 mg/L (MIC90, 0.12 mg/L and 0.25 mg/L, respectively), but voriconazole and AmB also had in vitro activity (MIC90, 0.5 mg/L and 1 mg/L, respectively). Differences in antifungal susceptibility within species and between species within genera support the need for testing individual patient isolates to guide therapy. The Sensititre® YeastOne® offers a practical alternative to the reference methodology for susceptibility testing of moulds.

Original languageEnglish
Pages (from-to)453-458
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Issue number4
Publication statusPublished - 1 Oct 2016


  • Antifungal susceptibility
  • Non-Aspergillus moulds
  • Sensititre
  • YeastOne

Cite this